|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Takahara T, Nitta H, Hasegawa Y, Itou N,
Takahashi M and Wakabayashi G: Using sorafenib for recurrent
hepatocellular carcinoma after liver transplantation - interactions
between calcineurin inhibitor: two case reports. Transplant Proc.
43:2800–2805. 2011. View Article : Google Scholar
|
|
3
|
Nitta H, Sasaki A, Fujita T, et al:
Laparoscopy-assisted major liver resections employing a hanging
technique: the original procedure. Ann Surg. 251:450–453. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sasaki A, Nitta H, Otsuka K, Takahara T,
Nishizuka S and Wakabayashi G: Ten-year experience of totally
laparoscopic liver resection in a single institution. Br J Surg.
96:274–279. 2009.PubMed/NCBI
|
|
5
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
|
|
6
|
Salhab M and Canelo R: An overview of
evidence-based management of hepatocellular carcinoma: a
meta-analysis. J Cancer Res Ther. 7:463–475. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thomas MB, Jaffe D, Choti MM, et al:
Hepatocellular carcinoma: consensus recommendations of the National
Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol.
28:3994–4005. 2010. View Article : Google Scholar
|
|
8
|
Izumi N, Asahina Y, Noguchi O, et al: Risk
factors for distant recurrence of hepatocellular carcinoma in the
liver after complete coagulation by microwave or radiofrequency
ablation. Cancer. 91:949–956. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Poon RT, Fan ST, Ng IO, Lo CM, Liu CL and
Wong J: Different risk factors and prognosis for early and late
intrahepatic recurrence after resection of hepatocellular
carcinoma. Cancer. 89:500–507. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arii S, Monden K, Niwano M, et al: Results
of surgical treatment for recurrent hepatocellular carcinoma;
comparison of outcome among patients with multicentric
carcinogenesis, intrahepatic metastasis, and extrahepatic
recurrence. J Hepatobiliary Pancreat Surg. 5:86–92. 1998.
View Article : Google Scholar
|
|
11
|
Miyata R, Tanimoto A, Wakabayashi G, et
al: Accuracy of preoperative prediction of microinvasion of portal
vein in hepatocellular carcinoma using superparamagnetic iron
oxide-enhanced magnetic resonance imaging and computed tomography
during hepatic angiography. J Gastroenterol. 41:987–995. 2006.
View Article : Google Scholar
|
|
12
|
Ma WL, Hsu CL, Yeh CC, et al: Hepatic
androgen receptor suppresses hepatocellular carcinoma metastasis
through modulation of cell migration and anoikis. Hepatology. Feb
9–2012.(Epub ahead of print).
|
|
13
|
Yamazaki K, Masugi Y and Sakamoto M:
Molecular pathogenesis of hepatocellular carcinoma: altering
transforming growth factor-beta signaling in hepatocarcinogenesis.
Dig Dis. 29:284–288. 2011. View Article : Google Scholar
|
|
14
|
Zheng F, Liao YJ, Cai MY, et al: The
putative tumour suppressor microRNA-124 modulates hepatocellular
carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut.
61:278–289. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fu J, Chen Y, Cao J, et al: p28(GANK)
overexpression accelerates hepatocellular carcinoma invasiveness
and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible
factor-1alpha pathways. Hepatology. 53:181–192. 2012. View Article : Google Scholar
|
|
16
|
Yao J, Liang L, Huang S, et al:
MicroRNA-30d promotes tumor invasion and metastasis by targeting
Galphai2 in hepatocellular carcinoma. Hepatology. 51:846–856.
2010.PubMed/NCBI
|
|
17
|
Mazzocca A, Liotta F and Carloni V:
Tetraspanin CD81-regulated cell motility plays a critical role in
intrahepatic metastasis of hepatocellular carcinoma.
Gastroenterology. 135:244–256. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sakon M, Nagano H, Nakamori S, et al:
Intrahepatic recurrences of hepatocellular carcinoma after
hepatectomy: analysis based on tumor hemodynamics. Arch Surg.
137:94–99. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gundersen GG and Bulinski JC: Selective
stabilization of microtubules oriented toward the direction of cell
migration. Proc Natl Acad Sci USA. 85:5946–5950. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hubbert C, Guardiola A, Shao R, et al:
HDAC6 is a microtubule-associated deacetylase. Nature. 417:455–458.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tran AD, Marmo TP, Salam AA, et al: HDAC6
deacetylation of tubulin modulates dynamics of cellular adhesions.
J Cell Sci. 120:1469–1479. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu H and Parsons JT: Cortactin, an
80/85-kilodalton pp60src substrate, is a filamentous actin-binding
protein enriched in the cell cortex. J Cell Biol. 120:1417–1426.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Luxton GW and Gundersen GG: HDAC6-pack:
cortactin acetylation joins the brew. Dev Cell. 13:161–162. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tsunoda K, Oikawa H, Tada H, et al:
Nucleus accumbens-associated 1 contributes to cortactin
deacetylation and augments the migration of melanoma cells. J
Invest Dermatol. 131:1710–1719. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zuo Q, Wu W, Li X, Zhao L and Chen W:
HDAC6 and SIRT2 promote bladder cancer cell migration and invasion
by targeting cortactin. Oncol Rep. 27:819–824. 2012.PubMed/NCBI
|
|
26
|
Park SY, Jun JA, Jeong KJ, et al: Histone
deacetylases 1, 6 and 8 are critical for invasion in breast cancer.
Oncol Rep. 25:1677–1681. 2011.PubMed/NCBI
|
|
27
|
Joshi A and Cao D: TGF-beta signaling,
tumor microenvironment and tumor progression: the butterfly effect.
Front Biosci. 15:180–194. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu J, Ustach C and Kim HR:
Platelet-derived growth factor signaling and human cancer. J
Biochem Mol Biol. 36:49–59. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lu X and Kang Y: Epidermal growth factor
signalling and bone metastasis. Br J Cancer. 102:457–461. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou HY, Pon YL and Wong AS: HGF/MET
signaling in ovarian cancer. Curr Mol Med. 8:469–480. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang JD, Nakamura I and Roberts LR: The
tumor microenvironment in hepatocellular carcinoma: current status
and therapeutic targets. Semin Cancer Biol. 21:35–43. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang XR, Xu Y, Yu B, et al: CD24 is a
novel predictor for poor prognosis of hepatocellular carcinoma
after surgery. Clin Cancer Res. 15:5518–5527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Inayoshi J, Ichida T, Sugitani S, et al:
Gross appearance of hepatocellular carcinoma reflects E-cadherin
expression and risk of early recurrence after surgical treatment. J
Gastroenterol Hepatol. 18:673–677. 2003. View Article : Google Scholar
|
|
34
|
Wong CC, Wong CM, Tung EK, Man K and Ng
IO: Rho-kinase 2 is frequently overexpressed in hepatocellular
carcinoma and involved in tumor invasion. Hepatology. 49:1583–1594.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yokomizo C, Yamaguchi K, Itoh Y, et al:
High expression of p300 in HCC predicts shortened overall survival
in association with enhanced epithelial mesenchymal transition of
HCC cells. Cancer Lett. 310:140–147. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Miyoshi A, Kitajima Y, Kido S, et al:
Snail accelerates cancer invasion by upregulating MMP expression
and is associated with poor prognosis of hepatocellular carcinoma.
Br J Cancer. 92:252–258. 2005.PubMed/NCBI
|
|
37
|
Aldana-Masangkay GI and Sakamoto KM: The
role of HDAC6 in cancer. J Biomed Biotechnol. 2011:8758242011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Grozinger CM, Hassig CA and Schreiber SL:
Three proteins define a class of human histone deacetylases related
to yeast Hda1p. Proc Natl Acad Sci USA. 96:4868–4873. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Haggarty SJ, Koeller KM, Wong JC,
Grozinger CM and Schreiber SL: Domain-selective small-molecule
inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin
deacetylation. Proc Natl Acad Sci USA. 100:4389–4394. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Haggarty SJ, Koeller KM, Wong JC, Butcher
RA and Schreiber SL: Multidimensional chemical genetic analysis of
diversity-oriented synthesis-derived deacetylase inhibitors using
cell-based assays. Chem Biol. 10:383–396. 2003. View Article : Google Scholar
|
|
41
|
Bazzaro M, Lin Z, Santillan A, et al:
Ubiquitin proteasome system stress underlies synergistic killing of
ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor.
Clin Cancer Res. 14:7340–7347. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Santo L, Hideshima T, Kung AL, et al:
Preclinical activity, pharmacodynamic and pharmacokinetic
properties of a selective HDAC6 inhibitor, ACY-1215, in combination
with bortezomib in multiple myeloma. Blood. 119:2579–2589. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kim HS, Vassilopoulos A, Wang RH, et al:
SIRT2 maintains genome integrity and suppresses tumorigenesis
through regulating APC/C activity. Cancer Cell. 20:487–499. 2011.
View Article : Google Scholar : PubMed/NCBI
|
